A study to ascertain whether hydrocortisone 17-butyrate (Locoid) 0.1% cream has any effect on the hypothalamic-pituitary-adrenal axis in children with skin diseases.
A study was conducted in eight children requiring topical corticosteroid treatment for dermatological disorders. The trial was carried out with hydrocortisone 17-butyrate (Locoid) 0.1% cream. The children were treated twice daily with Locoid cream applied to areas involving at least 20% of the body surface for a period of 2 to 3 weeks. Statistical analysis did not reveal any significant changes in plasma cortisol levels after treatment compared to pre-treatment baseline levels. No side-effects were reported.
D002056:Burns / Q000188:drug therapy; D002648:Child; D002675:Child, Preschool; D003879:Dermatologic Agents / Q000627:therapeutic use*; D004485:Eczema / Q000188:drug therapy; D006801:Humans; D006854:Hydrocortisone / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000097:blood* / Q000627:therapeutic use; D009450:Neurodermatitis / Q000188:drug therapy; D012871:Skin Diseases / Q000188:drug therapy*
D003879:Dermatologic Agents; C007975:hydrocortisone-17-butyrate; D006854:Hydrocortisone